ArticleBMC microbiology2025
Salivary microbiome in patients with benign prostatic hyperplasia: altered composition and its association with prostate-specific antigen.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundsMicrobial dysbiosis in the gut and urine has been implicated in patients with benign prostatic hyperplasia (BPH) in previous studies. Additionally, emerging evidence suggests that salivary dysbiosis is associated with various diseases and oral health conditions. Building on these findings, this study aimed to investigate whether BPH patients exhibit a distinct salivary microbiome. METHODS AND MATERIALS: We recruited a cohort of BPH patients (n = 50) and age- and BMI-matched healthy controls (HC; n = 50). Salivary samples were collected for 16S rRNA gene sequencing, and prostate-specific antigen (PSA) levels were measured.
resultsComparing the salivary microbial communities between BPH patients and HC revealed significant differences, with BPH patients exhibiting increased bacterial richness and diversity (FDR < 0.05). Further analysis identified 13 bacterial genera, including Clostridia-UCG-014, Oribacterium, and Filifactor, that were enriched in BPH patients. In contrast, 4 bacterial genera, such as Actinomyces, Lachnoanaerobaculum, and Rothia, were depleted in BPH patients (FDR < 0.05). Several bacterial genera showed potential as biomarkers for identifying BPH. Importantly, no correlation was observed between the bacterial community and PSA levels in BPH patients (P > 0.05).
conclusionsOur findings indicate that the salivary microbiome in BPH patients is dysbiotic, with altered richness, diversity, and specific taxonomic changes compared to healthy controls. Importantly, although prostate-specific antigen (PSA) levels are known to increase with prostate volume, our analysis found no significant association between the salivary microbiome and PSA levels in BPH patients. This suggests that while salivary dysbiosis is a feature of BPH, it does not appear to contribute directly to PSA dysregulation. Further research is needed to clarify the potential role of the salivary microbiome in BPH pathogenesis and its possible clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.